Education
About Us
Working with TipRanks
Follow Us
Initiator Pharma A/S (SE:INIT)
:INIT
INIT Stock Chart & Stats
kr2.93
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr2.93
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.56 - kr8.25
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr200.57M
Enterprise Valuekr221.43M
Total Cash (Recent Filing)kr4.70M
Total Debt (Recent Filing)kr2.19M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Feb 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.56 and its highest was kr8.25 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr200.57M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Feb 20, 2026 which is in 52 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on Nov 21, 2025. The company reported -kr0.093 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.093.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.093 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.786%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―